Catalyst Pharmaceuticals (CPRX) Cash from Financing Activities (2011 - 2026)

Catalyst Pharmaceuticals (CPRX) has 16 years of Cash from Financing Activities data on file, last reported at -$12.9 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 520.65% year-over-year to -$12.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$32.9 million (down 1330.42% YoY) and the FY2025 annual result came in at -$17.0 million, down 112.08% from the prior year.
• Cash from Financing Activities improved to -$12.9 million in Q1 2026, from -$25.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $141.0 million in Q1 2024 to a low of -$25.6 million in Q4 2025.
• A 5-year average of $6.0 million and a median of $149000.0 in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities plunged 925.0% — and 2024, when it surged 94563.76%.
• Tracing CPRX's Cash from Financing Activities over 5 years: stood at $2.3 million in 2022, then sank by 129.52% to -$665000.0 in 2023, then jumped by 766.62% to $4.4 million in 2024, then sank by 677.04% to -$25.6 million in 2025, then jumped by 49.68% to -$12.9 million in 2026.
• The last three Cash from Financing Activities figures came in at -$12.9 million (Q1 2026), -$25.6 million (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.